These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38546663)

  • 61. Is the ECOG-PS similar to the sarcopenia status for predicting mortality in older adults with cancer? A prospective cohort study.
    Sousa IM; Fayh APT
    Support Care Cancer; 2023 Jun; 31(6):370. PubMed ID: 37266669
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nutrition-inflammation marker enhances prognostic value to ECOG performance status in overweight or obese patients with cancer.
    Zhang X; Zhang Q; Tang M; Zhang KP; Zhang XW; Song MM; Ruan GT; Sun Q; Li W; Xu HX; Cong MH; Deng L; Shi HP
    JPEN J Parenter Enteral Nutr; 2023 Jan; 47(1):109-119. PubMed ID: 35589385
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
    Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
    Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Data-Driven Personalized Care in Lung Cancer: Scoping Review and Clinical Recommendations on Performance Status and Activity Level of Patients With Lung Cancer Using Wearable Devices.
    Aix SP; Núñez-Benjumea FJ; Cervera-Torres S; Flores A; Arnáiz P; Fernández-Luque L
    JCO Clin Cancer Inform; 2023 Sep; 7():e2300016. PubMed ID: 37922433
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
    Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
    J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer.
    Roman MA; Koelwyn GJ; Eves ND; Hornsby WE; Watson D; Herndon Ii JE; Kohman L; Loewen G; Jones LW
    Respirology; 2014 Jan; 19(1):105-8. PubMed ID: 23890224
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy.
    Aziz A; Fritsche HM; Gakis G; Kluth LA; Hassan Fa; Engel O; Dahlem R; Otto W; Gierth M; Denzinger S; Schwentner C; Stenzl A; Shariat SF; Fisch M; Burger M; Rink M
    Urol Oncol; 2014 Nov; 32(8):1141-50. PubMed ID: 24856977
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
    Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
    Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patient-Reported Functional Status in Outpatients With Advanced Cancer: Correlation With Physician-Reported Scores and Survival.
    Popovic G; Harhara T; Pope A; Al-Awamer A; Banerjee S; Bryson J; Mak E; Lau J; Hannon B; Swami N; Le LW; Zimmermann C
    J Pain Symptom Manage; 2018 Jun; 55(6):1500-1508. PubMed ID: 29496534
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Wearable device signals and home blood pressure data across age, sex, race, ethnicity, and clinical phenotypes in the Michigan Predictive Activity & Clinical Trajectories in Health (MIPACT) study: a prospective, community-based observational study.
    Golbus JR; Pescatore NA; Nallamothu BK; Shah N; Kheterpal S
    Lancet Digit Health; 2021 Nov; 3(11):e707-e715. PubMed ID: 34711377
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
    Karuturi MS; Cappelleri JC; Blum JL; Patel K; Telivala B; McCune S; Cuevas JD; Lakhanpal S; Montelongo MZ; Wang Y; Tripathy D; Rocque GB
    J Geriatr Oncol; 2024 Jan; 15(1):101670. PubMed ID: 38061288
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study.
    Martinez-Salamanca JI; Shariat SF; Rodriguez JC; Chromecki TF; Ficarra V; Fritsche HM; Kassouf W; Matsumoto K; Cabello LO; Seitz C; Tritschler S; Walton TJ; Zattoni F; Novara G
    BJU Int; 2012 Apr; 109(8):1155-61. PubMed ID: 21883847
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
    Diker O; Olgun P; Balyemez U; Sigit Ikiz S
    Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
    Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
    Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.
    Krishnan M; Kasinath P; High R; Yu F; Teply BA
    JCO Oncol Pract; 2022 Jan; 18(1):e175-e182. PubMed ID: 34351819
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors.
    Ozdemir Y; Yildirim BA; Topkan E
    J Neurooncol; 2016 Sep; 129(2):329-35. PubMed ID: 27306442
    [TBL] [Abstract][Full Text] [Related]  

  • 80. External validation and diagnostic value of the Elderly Functional Index version 2.0 for assessing functional status and frailty in older Danish patients with gastrointestinal cancer receiving chemotherapy: A prospective, clinical study.
    Jespersen E; Soo WK; Minet LR; Eshoj HR; King MT; Pfeiffer P; Möller S
    J Geriatr Oncol; 2024 Jan; 15(1):101675. PubMed ID: 38070322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.